Molecular hybridization, synthesis, and biological evaluation of novel chroman IKr and IKs dual blockers
摘要:
The combination of I-Kr and I-Ks blockade could lead to synergistic and safe class III anti-arrhythmic effect with the enhanced efficacy and reduced risk. On the rationale of structural hybridization of azimilide and HMR-1556, a novel series of IKr and IKs dual blockers were designed, synthesized and evaluated in vitro. One compound, 3r (CPUY11018), deserves further evaluation for its potent anti-arrhythmic activity and favorable cardiovascular profile. (C) 2009 Elsevier Ltd. All rights reserved.
DOI:
10.1016/j.bmcl.2009.01.022
作为产物:
描述:
4-(4-Propoxy-phenoxy)-but-2-yn-1-ol 在
air 作用下,
以
various solvent(s) 为溶剂,
反应 8.0h,
以40%的产率得到2,3-二氢-6-丙氧基-苯并吡喃-4-酮
参考文献:
名称:
Unexpected formation of chroman-4-ones during the synthesis of 4-hydroxymethyl-2H-chromenes from 4-aryloxybut-2-yn-1-ols
Chroman Compound, Processes for Its Preparation, and Its Pharmaceutical Use
申请人:You Qidong
公开号:US20080103307A1
公开(公告)日:2008-05-01
The present invention provided a chroman compound, the method of its preparation and pharmaceutical applications. The compound are represented by formula (I) and its pharmaceutical salt, where in :x is for O or S; n is for 2, 3 or 4; R
1
is 6-situ or 7-situ halogen, C
1-4
alkyl, C
1-4
alkyoxyl, benzyloxy, acylamino; R
2
is nitrogen-containing pentatomic or hexahydric substituted heterocyclic ring. The compound is useful to prepare anti-arrhythmic drugs, the reaction conditions of the method are mild, the raw material are plenty and easy to be obtained, and the operation and post-treatment are simple.
The combination of I-Kr and I-Ks blockade could lead to synergistic and safe class III anti-arrhythmic effect with the enhanced efficacy and reduced risk. On the rationale of structural hybridization of azimilide and HMR-1556, a novel series of IKr and IKs dual blockers were designed, synthesized and evaluated in vitro. One compound, 3r (CPUY11018), deserves further evaluation for its potent anti-arrhythmic activity and favorable cardiovascular profile. (C) 2009 Elsevier Ltd. All rights reserved.